Make your own free website on Tripod.com

Sponsors for KIN Research:

Google Groups
Subscribe to Medical Schools & Immunology Programs
Email:
Visit this group

tnplogo.gif

The KIN Consulting & Research Services Company





   The KIN Consulting and Research Services Company sells the analysis and visions of Chairman Natto (Published April 24th, 2006):

Join our campaign by submitting a complaint to the SEC! "SEC Contact Form" (Click HERE)

                        Chairman's Views on The Antibiotics Related Industry

   The simple truth of the matter is that the Pharmaceutical Industry is going to have a rather drastic slide.   The fact is that there is a disease that is killing white blood cells.   As the disease grows, the source for new antibodies subsequently declines.   They are inversely correlated  (rate of disease vs rate of new antibodies).   As a result there will be a drop in earnings forecasts, which will make it harder to raise money for the pharmaceutical companies.   This risk was not mentioned in the 10-K form of the following company.

   It is as if they do not know that the solution is theoretically The KIN Intravenous Solution (Glucose + Cloned White Blood Cells).   If anybody needs more information on the protocols for ex vivo production of white blood cells, then please contact the Chairman at khalidnatto@gmail.com.

                 Chairman's Research on "Applera Corporation-Celera Genomics Group " (ABI)

Applera Corporation-Celera Genomics Group (ABI)
chartsabi.gif
" Applera Corporation-Celera Genomics Group " Graph source Edgar Online Pro on April 21st, 2006

  The Following data is sourced from Yahoo Finance & the ANNUAL REPORT ON FORM 10-K For the fiscal year ended June 30, 2005 The overview of the company was:

  Overview:

  Applera Corp-Applied Biosystems Group (ABI) engages in the development and marketing of instrument-based systems, consumables, software, and services. It develops technologies and products to support applications in genomics research, such as sequencing, genotyping, and gene expression studies. The company’s products and services are used in analyze nucleic acids, such as DNA and RNA; small molecules; and proteins to make scientific discoveries, develop new pharmaceuticals, and conduct standardized testing. It offers various software products for laboratory information management systems. These products are designed to facilitate sample tracking, data collection, data analysis, and data mining. The company markets its products to life sciences industry and research community, including basic human disease research and genetic analysis performed by universities, government agencies, and other nonprofit organizations; pharmaceutical drug discovery, development, and manufacturing; agriculture research; forensic testing and human identification; biosecurit, which refers to products needed in response to the threat of biological terrorism and other malicious, accidental, and natural biological dangers; and food and environmental testing. The company was founded in 1937 and is headquartered in Foster City, California.

   Applera Corporation-Celera Genomics Group (CRA),principally engages in the discovery and development of targeted therapeutics for cancer, autoimmune, and inflammatory diseases in the United States. It leverages its proteomic, bioinformatic, and genomic capabilities to identify and validate drug targets, and to discover and develop small molecule therapeutics. The company has strategic collaborations with Abbott Laboratories to discover, develop, and commercialize targeted therapies for cancer; with General Electric Company to accelerate the discovery and development of new products for personalized, or targeted, medicine; and with Seattle Genetics, Inc. to discover, develop, and commercialize antibody-based therapies for cancer. Applera Corporation-Celera Genomics is headquartered in Norwalk, Connecticut. Applera Corporation-Celera Genomics Group is a division of Applera Corporation.

                            Highlights of Risks Related to Our (ABI) Business

   For further detail please review the 10 K Form in detail.

I. Factors Relating to Applied Biosystems

1. Rapidly changing technology in life sciences could make Applied Biosystems’ product line obsolete unless it continues to develop and manufacture new and improved products and services, and pursue new market opportunities.

2. Applied Biosystems relies on third parties for the manufacture of some of its products and also for the supply of some components of the products it manufactures on its own.

3. A significant portion of sales depends on customers’ capital spending policies that may be subject to significant and unexpected decreases.

4. A substantial portion of Applied Biosystems ’ sales is to customers at universities or research laboratories whose funding is dependent on both the amount and timing of funding from government sources.

5. Applied Biosystems is currently, and could in the future be, subject to lawsuits, arbitrations, investigations, and other legal actions with private parties and governmental entities, particularly involving claims for infringement of patents and other intellectual property rights, and it may need to obtain licenses to intellectual property from others.

6. Since Applied Biosystems’ business is dependent on foreign sales, fluctuating currencies will make revenues and operating results more volatile.

7. The future growth of Applied Biosystems depends in part on its ability to acquire complementary technologies through acquisitions, investments, or other strategic relationships or alliances, which may absorb significant resources, may be unsuccessful, and could dilute holders of Applera-Applied Biosystems stock.

8. Applied Biosystems’ businesses, particularly those focused on developing and marketing information-based products and services, depend on the continuous, effective, reliable, and secure operation of its computer hardware, software, and Internet applications and related tools and functions.

9. Applied Biosystems’ operations involve the use, manufacture, sale, and distribution of hazardous materials, and the mishandling of these hazardous materials could result in substantial liabilities and harm to Applied Biosystems.

10. Earthquakes could disrupt operations in California.

11. Applera-Applied Biosystems stock price may be volatile.

II. Factors Relating to Celera Genomics :

1. Celera Genomics has incurred net losses to date and may not achieve profitability. .

2. The marketing and distribution agreement with Applied Biosystems may not generate significant royalty payments.

3. Celera Genomics’ ability to develop and commercialize proprietary therapeutic products is unproven and several of its programs rely on the use of novel discovery methods.

4. For some of Celera Genomics’ research and product development programs, particularly its proteomics efforts, Celera Genomics needs access to human and other tissue samples from diseased and healthy individuals, other biological materials, and related clinical and other information, which may be in limited supply.

5. Therapeutic product candidates may never result in a commercialized product.

6. If Celera Genomics fails to maintain its existing collaborative relationships and enter into new collaborative relationships, or if collaborators do not perform under collaboration agreements, development of its therapeutic product candidates could be delayed.

7. If Celera Genomics or its collaborators fail to satisfy regulatory requirements for any therapeutic product candidate, Celera Genomics or its collaborators will be unable to complete the development and commercialization of that product.

8. Clinical trials may not be successful.

9. Clinical trials may take several years or more and can be very expensive.

10. Celera Genomics relies on other companies to conduct clinical trials.

11. Celera Genomics’ relies on suppliers for materials needed to manufacture compounds for clinical trials.

12. Celera Genomics relies on other companies to manufacture its therapeutic product candidates.

13. Celera Genomics' collaborations with outside experts may be subject to restriction and change.

14. The pharmaceutical industry is intensely competitive and evolving.

15. Introduction of new products may expose Celera Genomics to product liability claims.

16. Therapeutics discovery and development is a highly technical field and there is a competitive market for personnel with the expertise needed for the expansion of Celera Genomics’ business operations within this field.

17. Celera Genomics could incur liabilities relating to hazardous materials that it uses in its research and development activities.

18. Celera Genomics’ business depends on the continuous, effective, reliable, and secure operation of its computer hardware, software, and Internet applications and related tools and functions.

19. Celera Genomics’ competitive position depends on maintaining its intellectual property protection.

20. Celera Genomics may infringe the intellectual property rights of third parties, may become involved in expensive intellectual property legal proceedings, and may need to obtain licenses to intellectual property from others.

21. Ethical, legal, and social issues related to the use of genetic information and genetic testing may cause less demand for Celera Genomics’ products.

22. Celera Genomics may pursue acquisitions, investments, or other strategic relationships or alliances, which may consume significant resources, may be unsuccessful, and could dilute the holders of Applera-Celera Genomics stock.

23. Earthquakes could disrupt operations in California .

24. Applera-Celera Genomics stock price may be volatile.

25. Our company is subject to a class action lawsuit relating to its 2000 offering of shares of Applera-Celera Genomics stock that may be expensive and time consuming.

III. Factors Relating to Celera Diagnostics, a 50/50 Joint Venture between Applied Biosystems and Celera Genomics.

1. Celera Diagnostics’ ability to develop and commercialize proprietary diagnostic products is unproven.

2. Diagnostic product candidates may never result in a commercialized product.

3. If Celera Diagnostics or its collaborators fail to satisfy regulatory requirements for any diagnostic product candidate, they may be unable to complete the development and commercialization of that product.

4. Celera Diagnostics’ products may not be fully accepted by physicians and laboratories.

5. Ethical, legal, and social issues related to the use of genetic information and genetic testing may cause less demand for Celera Diagnostics’ products.

6. If insurance companies and other third-party payors do not reimburse doctors and patients for Celera Diagnostics’ tests, its ability to sell its products to the clinical diagnostics market will be impaired.

7. If Celera Diagnostics fails to maintain its existing collaborative relationships and enter into new collaborative relationships, or if collaborators do not perform under collaboration agreements, development of its diagnostic products could be delayed.

8. Celera Diagnostics does not have a sales and service capability in the clinical diagnostic market.

9. Celera Diagnostics has limited manufacturing capability and may encounter difficulties expanding Celera Diagnostics’ operations.

10. Celera Diagnostics’ research and product development depends on access to tissue and blood samples from diseased and healthy individuals, other biological materials, and related clinical and other information, which may be in limited supply.

11. Single suppliers or a limited number of suppliers provide key components of Celera Diagnostics’ products. If these suppliers fail to supply these components, Celera Diagnostics may be unable to satisfy product demand.

12. Celera Diagnostics’ operations involve the use, manufacture, sale, and distribution of hazardous materials, and the mishandling of these hazardous materials could result in substantial liabilities and harm to Celera Diagnostics.

13. Celera Diagnostics’ business depends on the continuous, effective, reliable, and secure operation of its computer hardware, software, and Internet applications and related tools and functions.

14. Celera Diagnostics’ competitive position depends on maintaining its intellectual property protection.

15. Celera Diagnostics may infringe the intellectual property rights of third parties, may become involved in expensive intellectual property legal proceedings, and may need to obtain licenses to intellectual property from others.

16. Introduction of new products may expose Celera Diagnostics to product liability claims.

17. The diagnostics industry is intensely competitive and evolving.

18. Earthquakes could disrupt operations in California.

IV. Risks Relating to a Capital Structure with Two Separate Classes of Common Stock

1. Stockholders of Applera Corporation are stockholders of one company and, therefore, financial effects on one group could adversely affect the other.

2. The market price of either class of our common stock may not reflect the separate performance of the group related to that common stock.

3. The market price of either class of our common stock may be affected by factors that do not affect traditional common stock.

4. Limits exist on the voting power of group common stock.

5. Stockholders may not have any remedies for breach of fiduciary duties if any action by directors or officers has a disadvantageous effect on either class of common stock.

6. Stock ownership could cause directors and officers to favor one group over the other.

7. Numerous potential conflicts of interest exist between the classes of common stock that may be difficult to resolve by our Board of Directors or that may be resolved adversely to one of the classes.

8. Our Board of Directors may change its management and allocation policies without stockholder approval to the detriment of either group.

9. Either Applied Biosystems or Celera Genomics may finance the other group on terms unfavorable to either group.

10. Celera Genomics could incur a higher tax liability than if it were a stand-alone taxpayer.

11. Holders of group common stock may receive less consideration upon a sale of assets than if the group were a separate company.

12. Our capital structure and variable vote per share may discourage acquisitions of a group or a class of common stock.

13. Decisions by our Board of Directors and officers that affect market values could adversely affect voting and conversion rights.

14. Provisions governing common stock could discourage a change of control and the payment of a premium for stockholders’ shares.

Recent articles on the medical industry:

For New Research Projects Contact The Chairman at Email: khalidnatto@gmail.com

First name:
Last name:
Email address:
Company:
Address 1:
Address 2:
City:
State:
Zip code:
Phone:
Request information on product?
Topic
  

===================================================================

Disclaimer of Warranty and Limitation of Liability
The information, products and services on this web site or letter are provided on an "AS IS," "WHERE IS" and "WHERE AVAILABLE" basis.  The KIN Consortium does not warrant the information or services provided herein or your use of this web site generally, either expressly or impliedly, for any particular purpose and expressly disclaims any implied warranties, including but not limited to, warranties of title, non-infringement, merchantability or fitness for a particular purpose. The KIN Consortium  will not be responsible for any loss or damage that could result from interception by third parties of any information or services made available to you via this web site. Although the information provided to you on this web site is obtained or compiled from sources we believe to be reliable, The KIN Consortium  cannot and does not guarantee the accuracy, validity, timeliness or completeness of any information or data made available to you for any particular purpose. Neither The KIN Consortium , nor any of its affiliates, directors, officers or employees, nor any third party vendor, will be liable or have any responsibility of any kind for any loss or damage that you incur in the event of any failure or interruption of this web site, or resulting from the act or omission of any other party involved in making this web site, the data contained herein or the products or services offered on this web site available to you, or from any other cause relating to your access to, inability to access, or use of the web site or these materials, whether or not the circumstances giving rise to such cause may have been within the control of The KIN Consortium  or of any vendor providing software or services. In no event will The KIN Consortium  or any such parties be liable to you, whether in contract or tort, for any direct, special, indirect, consequential or incidental damages or any other damages of any kind even if The KIN Consortium  or any other such party has been advised of the possibility thereof. This limitation on liability includes, but is not limited to, the transmission of any viruses which may infect a user's equipment, failure of mechanical or electronic equipment or communication lines, telephone or other interconnect problems (e.g., you cannot access your internet service provider), unauthorized access, theft, operator errors, strikes or other labor problems. The KIN Consortium  cannot and does not guarantee continuous, uninterrupted or secure access to the web site.

Proprietary Rights
All right, title and interest in this web site and any content contained herein is the exclusive property of The KIN Consortium , except as otherwise stated. Unless otherwise specified, this web site is for your personal and non-commercial use only and you may print, copy and download any information or portion of this web site for your personal use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, frame, create derivative works from, transfer, or otherwise use in any other way for commercial or public purposes in whole or in part any information, software, products or services obtained from this web site, except for the purposes expressly provided herein, without The KIN Consortium's prior written approval. If you copy or download any information or software from this web site, you agree that you will not remove or obscure any copyright or other notices or legends contained in any such information.

The KIN Consortium and other trademarks and service marks referenced herein are trademarks and service marks of The KIN Consortium . The names of other companies and third-party products or services mentioned herein may be the trademarks or service marks of their respective owners. You are prohibited from using any marks for any purpose including, but not limited to use as metatags on other pages or sites on the World Wide Web without the written permission of The KIN Consortium  or such third party, which may own the marks.

Pursuant to Section 512(c)(2) of the Copyright Act, The KIN Consortium  designates the following agent to receive notifications of claimed infringement: Khalid I Natto, The KIN Consortium , Email:
kalnatto2000@yahoo.com, Website: http://khalidnatto.tripod.com 

Use of Links
This web site contains links to third party web sites. These links are provided only as a convenience. The inclusion of any link is not and does not imply an affiliation, sponsorship, endorsement, approval, investigation, verification or monitoring by The KIN Consortium of any information contained in any third party web site. In no event shall The KIN Consortium be responsible for the information contained on that site or your use of or inability to use such site. You should also be aware that the terms and conditions of such site and the site's privacy policy may be different from those applicable to your use of this web site.

Feedback, subscriptions, ideas? Email: kalnatto2000@yahoo.com